Rare and Orphan Disease Trials

Engaging Patient Advocacy Leaders in Recruitment Strategies

Posted on digi By digi

In rare disease research, traditional recruitment channels often prove ineffective due to the small, dispersed, and diverse patient populations involved. Patient advocacy leaders—who have earned the trust of their communities—are emerging as powerful allies in clinical trial enrollment efforts. Their insights, communication platforms, and grassroots reach make them key players in designing and implementing recruitment strategies that resonate.
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials

Use of External Controls and Historical Data in Rare Disease Trials

Posted on digi By digi

One of the most pressing challenges in designing clinical trials for rare and ultra-rare diseases is the difficulty in recruiting sufficient participants for randomized control arms. The ethical dilemma of assigning patients to a placebo group in life-threatening or progressive diseases further complicates trial design. In response, researchers and sponsors are increasingly turning to external control arms and historical data as viable alternatives to traditional comparators.
Click to read the full article.

Adaptive Trial Designs, Rare and Orphan Disease Trials

Innovative Trial Designs for Genetic Disorders in Rare Disease Research

Posted on digi By digi

Rare diseases are often caused by monogenic or complex genetic mutations, and the clinical trial designs used in broader populations often fall short in addressing their unique challenges. Low prevalence, heterogeneity in mutation types, and rapid disease progression necessitate novel methodologies that optimize limited resources while generating robust evidence.
Click to read the full article.

Adaptive Trial Designs, Rare and Orphan Disease Trials

Targeting Undiagnosed Populations for Rare Disease Studies

Posted on digi By digi

One of the most significant barriers in rare disease clinical research is the “diagnostic odyssey” — the long, uncertain journey many patients endure before receiving a diagnosis. For some, this process takes years, if not decades. Unfortunately, during this delay, many remain invisible to the clinical research community, missing critical windows for therapeutic intervention.
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials

Sample Size Re-Estimation in Rare Disease Trials: Adaptive Approaches

Posted on digi By digi

Designing adequately powered clinical trials in the context of rare and ultra-rare diseases is inherently difficult due to the limited patient population and variability in disease progression. Traditional fixed sample size calculations often fall short when confronted with high inter-subject heterogeneity, poorly characterized endpoints, or evolving treatment landscapes.
Click to read the full article.

Adaptive Trial Designs, Rare and Orphan Disease Trials

Data Privacy Concerns in Patient Recruitment Campaigns

Posted on digi By digi

Rare disease clinical trials often target small, identifiable populations. This amplifies privacy risks during recruitment. Sharing health data—whether through registries, digital campaigns, or social media—must be handled with utmost care. Failure to respect privacy not only undermines trust but also risks violating global data protection regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA).
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials